Severe hyperinsulinism can be treated with somatostatin analogues. We studied growth and growth hormone(gh) in a patient with nesidioblastosis,treated with SMS 201-995. In a maroccan female with nesidioblastosis subtotal pancreatectomy was performed at an age of 4 weeks. Because of recurrent hypoglycaemia SMS 201-995 was instituted from an age of 1 1 month till 3.1 yrs.In a dose of 8 x 25pglday s.c. SMS 201-995resulted in normoglycaemia(portab1e infus~on pump.Ferring). The SMS treatment could be ceased at an age of 3.1 yrs. Growth velocity during the last 6 months of treatment was 5.2 cmlyr. In the year after discontinuation of therapy growth vel. increased to 12.2 cn yr.(CA:4.0 yr). During treatment SMC level was normal to slight1 elevated(l62 nglmL); maximum gh level during sleep decreased with the treatment period and was 8.2pgIL. just before discontinuntion.14 days off treatment max.gh had increased to 13yglL.
Conclusion: Chronic subcutaneous therapy(2.2 yrs) of SMS 201-995 was succesfull in preventing hypoglycaemic periods in a girl wit11 nesidioblastosis. Growth hormone secretion was gradually impaired during treatment. Catch up growth after discontinuation of therapy makes evident that growth was impaired during treatment with the somatostatin analogue SMS 201-995. Other authors have claimed that serial IGF-1 measurements may be a useful marker of reversibility of impaired growth in children with chronic inflammatory bowel disease. In order to evaluate parameters useful to predict growth retardation we followed 26 juvenile patients by estimation of growth velocity, weight gain, Best activity index (AI) and serum levels of a-1-glycoprotein (GP), albumin and IGF-1 over periods of 6-12 months. RIA-IGF-1 was measured in serum after acid-ethanol extraction using an antiserum supplied by the NHPP, Baltimore, Md. Age corrected IGF-1 levels at the end of, but not before an observation period of 6 months were correlated to growth velocity (r= 0.57; p<0.01) and weight gain (r= 0.44; pc0.05). % weight gain also was correlated to % change of IGF-1 levels (r: 0.50; ~(0.01). In contrast, there was no relation of IGF-1 to AI, GP and albumin levels, which again did not correlate to clinical parameters of growth. In conclusion: IGF-1 appears to be a better index of growth retardation compared to other parameters tested, but its value for the long-term follow-up of patients with chronic inflammatory bowel disease in limited. 
ACUTE LYMPHOCYTIC LEUKEMIA IN A PATIENT ON GROWTH HORMONE (GH) TREATMENT
With the availability of rDNA-GH, GH is applied in experimental trials to other groups of patients than with GH-deficiency. Most effects of GH and GH-factors are clear; an effect of malignant degeneration is unknown. Patient. In a 12.3 yrs old girl with idiopathic GII-deficiency pit-GI1 was instituted with 2 x 4 IUIwklim (12.7 IU/m2 /wk) at 5.5 yrs. At 6.6 yrs a pericarditis of unknown origin developed; pericardectomy was necessary. At 9.7 yrs GH treatment was stopped and resumed at 10.3 yrs with rDNA-GH 6 x 2 IU/wk/sc (12 IUlm'lwk). Throughout GH treatment growth was satisfactory. At 11.2 yrs she had muscle weakness resulting in failure to walk. Neurological, (including muscle biopsy) and laboratory investigation did not reveal abnormalities. Prednisone improved the weakness temporarily. She developed anaemia and hepato-splenomegaly and on examination of blood and bone marrow a diagnosis of a CALLA-positive acute lymphocytic leukemia was made. The leukemic cells did not show chromosomal aberrations. Cytotoxic treatment resulted in complete remission and disappearance of the muscle weakness. 17.6, 9.8, 7 kb, a minor 1 and 0.7 kb fragments), EcoRI (n=9 ; 7, 6.2, 4.1 and 1 kb) or Taq I (n=8; 10.4, 5, 3.6, 2.5 and 1.6 kb) were used. Taq I digestion of 2 Pygmy DNAs gave normal restriction patterns. . The IGF-1 receptor affinity did not change before and after incubation with these mitogens (1.24+/-0.21 versus 1.41+/-0.68 10(+9) M(-l);n=9).For PHA (lug/ ml) and OKT-3 (25ng/ml) stimulated lymphocytes we could demonstrate an increase of IGF-1 receptors / cell from 1640+/-350 to 2910+/-870 for PMA (n=7) and from 1770+/-390 to 2780+/-1280 for OKT-3 (n=9). In contrast,B-cells stimulated by PWM (10ug/ml) did not show any effect on IGF-1-binding.Stimulation of helper-and suppressor T-cells by OKT-4 and OKT-8 also did not influence IGF-1 binding.A dose dependent down regulation of IGF-1 receptor number could be demonstrated by addition of IGF-1 to cultured cells.In contrast to PHA and OKT-3,IGF-1 itself had no effect on DNA-or protein synthesis. Our results support the previous observation that IGF-1 binding to lymphocytes is increased by stimulation of T-but not of B-cells.
